Drugs / β-Sodium Glycerophosphate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT07060859 | Jan → Jun 2023 | — | Manar Ziad Foura-Matar | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | β-Sodium Glycerophosphate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07060859 ↗ |
| Route | Topical | “A topical combination of dexamethasone (anti-inflammatory), ascorbic acid (antioxidant), and β-sodium glycerophosphate (mineralization support) was applied directly to the...” NCT07060859 ↗ |